In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against
Leishmania
drug combinations
drug repurposing
intestinal organoids
pyrvinium pamoate plus miltefosine
pyrvinium pamoate plus paromomycin
Journal
Tropical medicine and infectious disease
ISSN: 2414-6366
Titre abrégé: Trop Med Infect Dis
Pays: Switzerland
ID NLM: 101709042
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
received:
12
12
2023
revised:
12
01
2024
accepted:
18
01
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
epublish
Résumé
One of the major drawbacks of current treatments for neglected tropical diseases is the low safety of the drugs used and the emergence of resistance. Leishmaniasis is a group of neglected diseases caused by protozoa of the trypanosomatidae family that lacks preventive vaccines and whose pharmacological treatments are scarce and unsafe. Combination therapy is a strategy that could solve the above-mentioned problems, due to the participation of several mechanisms of action and the reduction in the amount of drug necessary to obtain the therapeutic effect. In addition, this approach also increases the odds of finding an effective drug following the repurposing strategy. From the previous screening of two collections of repositioning drugs, we found that pyrvinium pamoate had a potent leishmanicidal effect. For this reason, we decided to combine it separately with two clinically used leishmanicidal drugs, miltefosine and paromomycin. These combinations were tested in axenic amastigotes of
Identifiants
pubmed: 38393119
pii: tropicalmed9020030
doi: 10.3390/tropicalmed9020030
pii:
doi:
Types de publication
Journal Article
Langues
eng